Femasys Inc. and Kebomed are joining forces to commercialize FemBloc Permanent Birth Control in France and the Benelux region (The Netherlands, Belgium, and Luxembourg).

With France representing Europe’s largest single-market opportunity, this collaboration significantly expands access to the only non-surgical permanent birth control option and represents a major milestone in Femasys’ European growth strategy following recent CE mark approval, company bigwigs claim.

“We are thrilled to partner with Kebomed, a distributor with deep expertise in women’s health and strong market access in key markets across Europe,” Femasys Founder/CEO Kathy Lee-Sepsick said. “France is a large market opportunity for FemBloc in the region, and Kebomed’s established infrastructure and gynecology-focused portfolio make them the ideal partner to expand access, accelerate adoption, and unlock significant growth potential.”

FemBloc is marketed as a first-of-its-kind, non-surgical solution for permanent birth control that uses a patented delivery system to place a proprietary blended polymer into both fallopian tubes, which safely degrades and forms natural scar tissue for permanent occlusion. In contrast to surgical sterilization, FemBloc eliminates the risks of anesthesia, infection, and recovery downtime, making it safer, more accessible, and significantly more cost-effective. With no comparable alternatives on the market, FemBloc represents a disruptive advancement with broad global potential.

“FemBloc represents a revolutionary advancement in women’s health. With our strong presence in gynecology and established European network, we are well positioned to drive adoption in France and Benelux,” Kebomed Europe AG Chairman Søren Dalmark Kornerup stated. “Adding this permanent contraceptive solution further strengthens our women’s health portfolio and reinforces our leadership in this important field.”

Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its patent-protected portfolio of in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the United States and key international markets. Femasys’ fertility portfolio includes FemaSeed Intratubal Insemination, a first-step infertility treatment, and FemVue, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrates FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.¹

FemBloc permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June of 2025, the U.K. in August 2025, and New Zealand in September 2025. Commercialization of this safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.² For U.S. Food and Drug Administration approval, enrollment is ongoing in the FINALE pivotal trial.

Kebomed Europe AG is an independent distributor of medical devices with more than 30 years of heritage and a strong footprint across Europe. Founded in 1995 in Scandinavia, the company expanded through acquisitions in the U.K., Benelux, Norway, France, Switzerland, Germany, and Austria, establishing itself as one of the few truly pan-European platforms. Women’s health has long been a strategic focus for Kebomed, supported by its close relationship with LiNA Medical, an innovator in minimally invasive gynecology owned by the same family. Through this connection, Kebomed distributes LiNA products in select European markets, strengthening its portfolio and reinforcing its leadership and deep clinical expertise in this important therapeutic area.

References
¹ Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.
² Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.